NxThera, Inc., a medical device company pioneering the application of its Convective Water Vapor Energy (WAVE®) technology to treat endourological conditions, today announced publication of a recent economic analysis which demonstrates its minimally invasive Rezūm System to be a cost-effective and durable solution in treating benign prostatic hyperplasia (BPH).
Magellan Health, Inc. (NASDAQ: MGLN) has long been the national leader in the use of digital innovation to help those struggling with various medical and behavioral conditions, including Substance Use Disorders (SUD). As a pioneer in the use of digital therapeutics and computerized cognitive behavioral therapy (CCBT), Magellan has engaged in a new initiative designed to measure clinical outcomes in patients with SUD by leveraging reSET®, the first ever FDA cleared prescription digital therapeutic from PEAR Therapeutics.
NxThera, Inc., a medical device company pioneering the application of its Convective Water Vapor Energy (WAVE®) platform technology to treat endourological conditions, announced the three-year outcomes data from the Rezūm II pivotal clinical trial of its minimally invasive Rezūm® System, demonstrating significant, effective and durable lower urinary tract symptom (LUTS) relief, improved quality of life and preserved sexual function for men treated for benign prostatic hyperplasia (BPH). The outcomes were recently published in the January 2018 issue of Urology.
SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System® (“iFuse”), a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, announced that Blue Cross Blue Shield Association (BCBSA), after an extensive review of all existing peer-reviewed published clinical safety and effectiveness data, has assigned triangular implants for SI joint fusion a “Moderate” quality evidence recommendation.
PEAR Therapeutics, the leader in prescription digital therapeutics, today announced that it has successfully closed a $50 million Series B financing led by Temasek.
Three years after stepping down from the top job at Entergy Corp., New Orleans’ lone Fortune 500 firm, Wayne Leonard’s retirement took a bad turn. After being diagnosed with stage 4 lung cancer,Leonard was referring to Ochsner Medical Center on Jefferson Highway, where he is involved in a new initiative designed to tailor a cancer patient’s treatment to information found within their tumor’s genetic profile. That information can be used to match patients with early-phase clinical trials and enable them to participate in innovative therapies still under development.